Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand

PharmacoEconomics
Naruemon BamrungsawadPiyameth Dilokthornsakul

Abstract

Intravenous immunoglobulin (IVIG) has been shown to be effective in treating steroid-refractory dermatomyositis (DM). There remains no evidence of its cost-effectiveness in Thailand. Our objective was to estimate the cost utility of IVIG as a second-line therapy in steroid-refractory DM in Thailand. A Markov model was developed to estimate the relevant costs and health benefits for IVIG plus corticosteroids in comparison with immunosuppressant plus corticosteroids in steroid-refractory DM from a societal perspective over a patient's lifetime. The effectiveness and utility parameters were obtained from clinical literature, meta-analyses, medical record reviews, and patient interviews, whereas cost data were obtained from an electronic hospital database and patient interviews. Costs are presented in $US, year 2012 values. All future costs and outcomes were discounted at a rate of 3% per annum. One-way and probabilistic sensitivity analyses were also performed. Over a lifetime horizon, the model estimated treatment under IVIG plus corticosteroids to be cost saving compared with immunosuppressant plus corticosteroids, where the saving of costs and incremental quality-adjusted life-years (QALYs) were $US4738.92 and 1.96 QALYs, respe...Continue Reading

References

Feb 6, 1992·The New England Journal of Medicine·B SigurgeirssonE Allander
Dec 30, 1993·The New England Journal of Medicine·M C DalakasS McCrosky
Jul 1, 1997·Drugs·P Cherin
Dec 8, 1998·Muscle & Nerve·B A PhillipsF L Mastaglia
Apr 25, 2000·Scandinavian Journal of Rheumatology·J VencovskýF Charvát
Sep 27, 2003·Lancet·Marinos C Dalakas, Reinhard Hohlfeld
Nov 26, 2003·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·M S Klein-GitelmanL M Pachman
May 20, 2004·JAMA : the Journal of the American Medical Association·Marinos C Dalakas
Feb 16, 2006·Clinical Rheumatology·A AirioM Hakala
Mar 1, 2006·International Immunopharmacology·Marinos C Dalakas
Sep 13, 2006·Clinics in Dermatology·Jeffrey P Callen, Robert L Wortmann
Apr 22, 2008·Journal of the American Academy of Dermatology·Luciano J Iorizzo, Joseph L Jorizzo
Nov 13, 2009·Autoimmunity Reviews·Sergio Prieto, Josep M Grau
Feb 4, 2010·Nature Reviews. Rheumatology·Marinos C Dalakas
Jun 12, 2010·International Journal of Rheumatic Diseases·Sally CoxPeter Roberts-Thomson
Nov 1, 2008·Therapeutic Advances in Neurological Disorders·Marinos C Dalakas
Mar 3, 2011·Current Treatment Options in Neurology·Marinos C Dalakas
Jul 12, 2011·Autoimmunity Reviews·Isabelle Marie, Luc Mouthon
Jul 30, 2011·Current Opinion in Neurology·Marinos C Dalakas
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sirinart Tongsiri, John Cairns
Apr 14, 2012·Muscle & Nerve·Daniel E FurstAncilla W Fernandes
Mar 25, 2014·Journal of Neurology·Janneke van de VlekkertMarianne de Visser

❮ Previous
Next ❯

Citations

Jun 2, 2018·Clinical and Experimental Dermatology·F GalimbertiA P Fernandez
Sep 3, 2017·Wiener medizinische Wochenschrift·Lyubomir A DourmishevLjubka G Miteva
Sep 27, 2019·World Journal of Pediatrics : WJP·Jian-Qiang WuAnn M Reed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.